Search Results
Nov 13, 2025, 06:59 ET Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
B of the SIGNAL-AA Phase 2a clinical trial, Q32 Bio's expectations and assumptions regarding the timing of the Part A OLE of the SIGNAL-AA Phase 2a clinical trial and the anticipated timing of its completion of dosing and clinical activity, and Q32 Bio's beliefs, expectations and assumptions regarding
More news about: Q32 Bio
Nov 12, 2025, 08:03 ET Cell Surface Bio Launches VeRSa-Select™ to Deliver the Highest Quality Custom Antibodies for Validating Difficult Therapeutic Targets
challenging cell surface proteins and other targets. About Cell Surface Bio Cell Surface Bio's mission is to provide researchers with only the highest quality antibodies, because as fellow scientists, we know that your time in the lab is valuable.
More news about: Cell Surface Bio
Nov 11, 2025, 09:00 ET Strategic Partnership Between Sanyou Bio and Yugong Bio to Accelerate Expansion in High-End Synthetic Enzyme Market
from "Discovery" to "Delivery": Sanyou Bio will utilize its trillion-scale molecular library and efficient screening platform to support Yugong Bio's enzyme optimization and engineering for specific application scenarios. Yugong Bio will leverage its mature enzyme product R&D and large-scale production
More news about: Sanyou Bio
Nov 10, 2025, 08:30 ET Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B
study in the Asia-Pacific region. Cohort 4 evaluates a novel sequential combination treatment strategy for hepatitis B virus (HBV), utilizing Brii Bio's therapeutic vaccine, BRII-179, to prime and enrich patients, with a goal to improve responsiveness to therapies potentially offering a functional cure.
More news about: Brii Biosciences Limited
Nov 06, 2025, 07:27 ET MavriX Bio Announces First Patient Dosed in ASCEND-AS Trial of MVX-220, Investigational Gene Therapy for Angelman Syndrome
neurodevelopmental disorders." Developed at the University of Pennsylvania with funding from FAST, MVX-220 was advanced through AS2Bio's drug development accelerator and licensed to MavriX Bio for clinical development following a research collaboration with GEMMABio.
More news about: AS2Bio
Nov 04, 2025, 08:15 ET Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801
scalable, off-the-shelf immunotherapy candidate. "The invitation to present at ASH 2025 highlights international recognition of Grit Bio's leadership in advancing in vivo CAR-T innovation," said Dr. Yarong Liu, Chairman and CEO of Grit Biotherapeutics. "Our GT801 platform represents a paradigm
More news about: Grit Biotherapeutics Co., Ltd.
Nov 03, 2025, 09:00 ET Sanyou Bio and Shanghai ZJ Bio-Tech Sign Strategic Cooperation Agreement on Automated Development of Innovative Biologics to Jointly Tackle R&D Bottlenecks and Provide New Momentum for Innovative Drug R&D
context of intelligent healthcare, ultimately benefiting patient populations globally. This cooperation will fully leverage Sanyou Bio's strengths in its globally leading AI-powered Super-Trillion Molecule Library (AI-STAL) technology, as well as intelligent drug screening and preclinical
More news about: Sanyou Bio
Nov 03, 2025, 08:00 ET Matica Bio, a CDMO Leader in Oncolytic Virus Manufacturing, Partners with Calidi Biotherapeutics to Advance Calidi's Project Toward IND
This collaboration reinforces Matica Bio's growing reputation as one of the few CDMOs globally with proven, end-to-end capabilities, especially in oncolytic virus manufacturing. The company has
More news about: Matica Biotechnology, Inc.
Oct 31, 2025, 13:51 ET Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain receive the 2025 Merkin Prize at the Broad Institute for chimeric antigen receptor (CAR) T-cell therapy
autoimmune and infectious diseases [Bios of June, Levine, Rivière, and Sadelain].
More news about: Broad Institute
Oct 29, 2025, 16:38 ET Kyowa Hakko Bio Evolves: Kyowa Hakko Bio Italia Named European Gateway with Expanded EMEA Role and Health Science Focus
KHIT strengthens Kyowa Hakko Bio's regional leadership with new science marketing capabilities to accelerate growth and collaboration across Europe, the Middle East, and Africa. MILAN,
More news about: Kyowa Hakko U.S.A
Oct 29, 2025, 13:28 ET Avobis Bio Presents Positive Primary Analysis Results from the Randomized Multicenter STOMP2 Clinical Trial at a Plenary Session of the American College of Gastroenterology's Annual Scientific Meeting
ClinicalTrials.gov. About Avobis Bio Avobis Bio's mission is to transform life for patients with debilitating conditions by harnessing the power of implantable biology to develop curative therapies
More news about: Avobis Bio
Oct 29, 2025, 09:00 ET Wheeler Bio Announces Strategic Partnership with Mitsubishi Corporation to Accelerate Asia-Pacific Business Development
ModularCMC™ platform and state-of-the-art cGMP biomanufacturing facility in Oklahoma City. As the demand for U.S. based biomanufacturing increases, Wheeler Bio's ModularCMC™ platform is well positioned to streamline the path from discovery to clinical development for antibody-based therapeutics, with maximum
More news about: Wheeler Bio, Inc.
Oct 29, 2025, 07:00 ET The Honours 2025: Three extraordinary women redefining what yachting can do for the world
2025 Images and bios available here. About The Superyacht Life Foundation
More news about: The Superyacht Life Foundation
Oct 28, 2025, 08:40 ET Greg Nelson and Judy Alexander Cory to Receive Lifetime Achievement Awards at the MUAHS Awards
CLICK HERE For Bios and Headshots:
More news about: Make-Up Artists & Hair Stylists Guild (MUAHS, IATSE Local 706)
Oct 27, 2025, 14:00 ET Cizzle Bio CEO Bill Behnke Moderates High-Profile Panel on Value-Based Cancer Diagnostics at 2025 AVBCC Summit
value when it reaches patients early and equitably." -- Cizzle Bio CEO Bill Behnke The Oct. 22 discussion underscored Cizzle Bio's commitment to redefining early detection through advancing blood-based, biomarker-driven diagnostics for lung and gastric cancers that integrate clinical,
More news about: Cizzle Bio
Oct 27, 2025, 10:20 ET Chromatin Bioscience Announces Collaboration with Purespring Therapeutics
nephrology company leading the development of targeted, first-in-class genetic therapies to preserve kidney function. The collaboration leverages Chromatin Bio's proprietary synthetic promoter design platform, chromatinLENS, to develop highly cell-selective promoters tailored to support Purespring's innovative
More news about: CHROMATIN BIOSCIENCE LTD
Oct 27, 2025, 10:15 ET Chromatin Bioscience Announces Collaboration with Purespring Therapeutics
nephrology company leading the development of targeted, first-in-class genetic therapies to preserve kidney function. The collaboration leverages Chromatin Bio's proprietary synthetic promoter design platform, chromatinLENS, to develop highly cell-selective promoters tailored to support Purespring's innovative
More news about: CHROMATIN BIOSCIENCE LTD
Oct 24, 2025, 08:00 ET ChemDiv Extends Discovery and Early Development Partnership with Mondego Bio on Best-in-Class PTPN2 Immuno-Oncology Program
development partnership with Mondego Bio to advance the company's best-in-class immuno-oncology program targeting PTPN2. The announcement follows Mondego Bio's successful Series A financing led by Biovance Capital with participation from OrbiMed Advisors and Torrey Pines Investment, underscoring strong momentum
More news about: ChemDiv
Oct 22, 2025, 15:46 ET Pivot Bio CEO Chris Abbott Featured at the World Food Prize Foundation's 2025 Norman E. Borlaug International Dialogue
Pivot Bio's Chief Executive Officer Chris Abbott joined global thought leaders for the session "Innovating the Future Now," moderated by Isis Almeida, Chicago
More news about: Pivot Bio, Inc
Oct 22, 2025, 07:39 ET Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma
Ms. Jinhua Zhang, Founder, Chairwoman and CEO of IASO Bio, remarked: "We are delighted that the remarkable research results of IASO Bio's independently developed anti-GPRC5D CAR-T product, RD118, for the treatment of R/R MM have been published in the prestigious international journal Blood.
More news about: IASO Bio
Oct 21, 2025, 06:59 ET Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
www.sec.gov. Any such risks and uncertainties could materially and adversely affect Q32 Bio's results of operations and its cash flows, which would, in turn, have a significant and adverse impact on Q32 Bio's stock price. Q32 Bio cautions you not to place undue reliance on any forward-looking statements,
More news about: Q32 Bio
Oct 20, 2025, 11:50 ET SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Palisade Bio, Inc. (NASDAQ: PALI)
it is investigating Palisade Bio, Inc. (NASDAQ: PALI) on behalf of the company's shareholders. The investigation seeks to determine whether Palisade Bio's directors breached their fiduciary duties in connection with recent corporate actions.
More news about: Purcell & Lefkowitz LLP
Oct 20, 2025, 08:33 ET Surf Bio to Present SnapShot™ Platform at PODD 2025, Showcasing Potential to Transform Subcutaneous Delivery of High-Dose Biologic Therapies
Surf Bio's CEO, Bryan Mazlish, will deliver a presentation titled, "Surf SnapShot™ Technology: Ultra-Concentrated Subcutaneous Biologics via Standard Manufacturing
More news about: Surf Bio, Inc.
Oct 16, 2025, 08:45 ET Cell Publishes Breakthrough Research Results of IASO Bio's Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis
congratulations to Professor Wei Wang and his team as the principal investigators for this accomplishment. This achievement further highlights IASO Bio's pioneering innovation capabilities in the field of CAR-T cell therapy. Autoimmune diseases are the key therapeutic focus for
More news about: IASO Bio
Oct 15, 2025, 10:00 ET CJ BIO Showcases Science-Backed Nutrition Solutions at SSG 2025
comprehensive approach to holistic wellness. Join UsAt Booth #2865, visitors can explore CJ BIO's trusted Nutrition Solutions developed in response to global trends in muscle health, beauty, and holistic wellness. Interested visitors can learn more
More news about: CJ BIO